Altamira Therapeutics Ltd.

Disclaimer : Sections of this page are auto-generated by Artificial Intelligence and shall not be understood as Investment Advice
This page was updated : 2023-05-05 11:09:02 UTC

Altamira Therapeutics Ltd. has announced positive results from a Phase 2 trial with AM-125 in acute vestibular syndrome, which have been published in a leading peer-reviewed journal. This news has caused the company's stock to rise by 64%. Additionally, Altamira Therapeutics has reported positive conclusions from an independent meta-analysis of clinical studies with betahistine in the treatment of the most common cause of vertigo. The company is also listed as one of four penny stocks to watch if you're playing the "stock market ...

Based on these articles
  1. Best Penny Stocks Today? 3 Under $1 To Watch Now
  2. 3 Tips for Day Trading Penny Stocks in 2023
Business Overview

As an investment analyst, Altamira Therapeutics Ltd.'s business model can be evaluated based on several factors such as the company's target market, revenue streams, competitive advantage, and growth potential. Altamira Therapeutics Ltd. is a clinical-stage biopharmaceutical company that focuses on developing gene therapies for rare genetic diseases. The company's target market is patients with rare genetic diseases who have limited treatment options. Altamira's revenue streams primarily come from the development and commercialization of its ...

Yahoo - Business Overview

Altamira Therapeutics Ltd., a clinical-and commercial-stage biopharmaceutical company, engages in the development of therapeutics that address various unmet medical needs in Switzerland, the United States, Europe, and Australia. The company develops OligoPhore/SemaPhore, a platform for delivery of oligonucleotides, such as small interfering ribonucleic acid or messenger RNA into target cells. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also ...

Risk Rating (Yahoo)


ESG Score (Yahoo)


Market Cap (USD)

6 M

AI Rank (finclout)


Flags & Key Risks
Negative Revenue Trend Negative Return on Equity Currency not in USD Country on Blacklist Current Ratio less than one Negative profit margins Negative EV to Ebitda
  • Regulatory approval for Altamira's products may not be obtained, which could result in significant financial losses for investors.
  • Altamira is a clinical-stage company, and its products are still in development. There is no guarantee that they will be successful in clinical trials or receive regulatory approval.
  • Altamira may face competition from larger, more established companies with greater resources and experience in the industry.
  • Altamira's success is dependent on the ability of its management team to execute its business plan effectively.
  • Altamira may require additional funding to continue its operations, which could dilute the value of existing shares and negatively impact investors.

SWOT Analysis


Altamira Therapeutics Ltd. has a strong and experienced management team with a proven track record in the biotech industry. The company has a robust ...  


Altamira Therapeutics Ltd. is a relatively small company with limited resources, which may limit its ability to compete with larger players in the industry. The company is heavily dependent on the success of its pipeline products, which may be subject to regulatory and clinical trial risks. Altamira Therapeutics Ltd. may face challenges in attracting and retaining top talent in a highly competitive industry.


Altamira Therapeutics Ltd. has the opportunity to expand its pipeline through strategic partnerships and collaborations with other companies in the industry. The company can also explore new markets and geographies to increase its customer base and revenue streams. Altamira Therapeutics Ltd. can leverage advances in technology and research to develop more effective and efficient gene therapies.


Altamira Therapeutics Ltd. operates in a highly competitive and rapidly evolving industry, which may pose a threat to its market position and growth prospects. The company may face regulatory and legal challenges that could delay or prevent the commercialization of its products. Altamira Therapeutics Ltd. may also face challenges in securing funding for its research and development activities.

Thesis for Altamira Therapeutics Ltd.


Altamira Therapeutics Ltd. has a strong pipeline of gene therapy candidates that have shown promising results in preclinical studies. With the increasing demand for gene therapies, the company is well-positioned to capitalize on this growing market. Addit ...


Altamira Therapeutics Ltd. is a relatively new company with a limited track record. While the company has promising gene therapy candidates in its pipeline, it is still in the early stages of development and has not yet brought any products to market. As ...


Altamira Therapeutics Ltd. operates in a highly competitive and rapidly evolving market. While the company has promising gene therapy candidates in its pipeline, there is no guarantee that these candidates will be successful in clinical trials or receive ...

News Coverage

6 days ago @OpenOutcrier
$CYTO (+33.7% pre) Altamira Therapeutics (CYTO) Reports Positive Top-Line Data from Bentrio Clinical Trial in Seaso…
#CYTO #cyto #seaso #bentrio #altamira #therapeutics
6 days ago @ACInvestorBlog
$CYTO took some at 91c for a swing trade
#CYTO #tradeacinvestorblog #swing #cyto #took #CYTO
14 days ago @gurgavin
#CYTO #cyto #smallest #seems #nasdaq #co
26 days ago @ACInvestorBlog
$CYTO long-term chart. The declining EMA100 has been the major res for the stock everytime it spikes higher. Defini…
#CYTO #everytime #spikes #declining #cyto #chart
26 days ago @ACInvestorBlog
$CYTO took profits from yest entry bc of the market weakness. I will see if will re-enter or not. The swing idea worked.
#CYTO #yest #cyto #acinvestorblog #worked #weakness
26 days ago @ACInvestorBlog
$CYTO big gap up in PM oh boy, a heavily shorted name with a very low float !!
#CYTO #oh #acinvestorblog #cyto #heavily #name
26 days ago @ACInvestorBlog
$CYTO another beaten down low float bio name like HCDI heavily shorted (Finviz and TD Ameritrade shows 110% short f…
#CYTO #finviz #ameritrade #hcdi #shows #heavily
26 days ago @ACInvestorBlog
$CYTO took a swing position for the coming days. Low float beaten down bio names are getting HOT again, so i love t…
#CYTO #swing #beaten #cyto #names #love
26 days ago @ACInvestorBlog
$CYTO some hits in AHs
#CYTO #hits #ahsacinvestorblog #cyto #CYTO
26 days ago @ACInvestorBlog
$CYTO heavily shorted low float bio name making new highs in AHs
#CYTO #ahsacinvestorblog #heavily #cyto #name #making
1 month ago @SqueezeFinder
@KEISUKEA16 $CYTO is currently at 63% Squeezability. You can easily check my scores on any ticker here:
#CYTO #squeezability #cyto #easily #scores #check
1 month ago @SqueezeFinder
Pretty good scores here on $CYTO
#CYTO #cyto #scores #pretty #good #CYTO
1 month ago @DilutionTracker
Daily Dilution Update 04/13 Offering $GCTK $10m @ $1.36 $CYTO RW, then lowered conversion price on conv notes…
#CYTO #cyto #lowered #conversion #conv #gctk
1 month ago @ACInvestorBlog
$CYTO ripping higher in AHs
#CYTO #ripping #cyto #ahsacinvestorblog #higher #CYTO
1 month ago @ACInvestorBlog
$CYTO Altamira Therapeutics Reports Positive Conclusions from Independent Meta-Analysis of Clinical Studies with Be…
#CYTO #cyto #altamira #studies #conclusions #therapeutics
1 month ago @OpenOutcrier
$CYTO Altamira Therapeutics (CYTO) Reports Positive Conclusions from Independent Meta-Analysis of Clinical Studies…
#CYTO #cyto #altamira #studies #conclusions #therapeutics
No research found for
No filings found for
No lawsuits found for
Offcanvas top
Offcanvas left






Offcanvas bottom
Some text as placeholder. In real life you can have the elements you have chosen. Like, text, images, lists, etc.